Literature DB >> 27198054

Effectiveness of azacitidine in higher-risk myelodysplastic syndromes.

A G Dinmohamed1, Y van Norden2, A A van de Loosdrecht3, M Jongen-Lavrencic1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27198054     DOI： 10.1038/leu.2016.117

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry.

Authors:  A G Dinmohamed; Y van Norden; O Visser; E F M Posthuma; P C Huijgens; P Sonneveld; A A van de Loosdrecht; M Jongen-Lavrencic
Journal:  Leukemia       Date:  2015-09-15       Impact factor: 11.528

2.  Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply.

Authors:  T Bernal; P Martínez-Camblor; J Sánchez-García; G Sanz
Journal:  Leukemia       Date:  2016-01-12       Impact factor: 11.528

3.  Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.

Authors:  Jurjen Versluis; Carin L E Hazenberg; Jakob R Passweg; Wim L J van Putten; Johan Maertens; Bart J Biemond; Matthias Theobald; Carlos Graux; Jurgen Kuball; Harry C Schouten; Thomas Pabst; Bob Löwenberg; Gert Ossenkoppele; Edo Vellenga; Jan J Cornelissen
Journal:  Lancet Haematol       Date:  2015-09-18       Impact factor: 18.959

4.  Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.

Authors:  T Bernal; P Martínez-Camblor; J Sánchez-García; R de Paz; E Luño; B Nomdedeu; M T Ardanaz; C Pedro; M L Amigo; B Xicoy; C del Cañizo; M Tormo; J Bargay; D Valcárcel; S Brunet; L Benlloch; G Sanz
Journal:  Leukemia       Date:  2015-05-06       Impact factor: 11.528

5.  Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years.

Authors:  J J Cornelissen; J Versluis; J R Passweg; W L J van Putten; M G Manz; J Maertens; H B Beverloo; P J M Valk; M van Marwijk Kooy; P W Wijermans; M R Schaafsma; B J Biemond; M-C Vekemans; D A Breems; L F Verdonck; M F Fey; M Jongen-Lavrencic; J J W M Janssen; G Huls; J Kuball; T Pabst; C Graux; H C Schouten; A Gratwohl; E Vellenga; G Ossenkoppele; B Löwenberg
Journal:  Leukemia       Date:  2014-11-27       Impact factor: 11.528

6.  A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia.

Authors:  N H Russell; L Kjeldsen; C Craddock; A Pagliuca; J A Yin; R E Clark; A Howman; R K Hills; A K Burnett
Journal:  Leukemia       Date:  2014-11-07       Impact factor: 11.528

7.  Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories.

Authors:  Jan J Cornelissen; Dimitri Breems; Wim L J van Putten; Alois A Gratwohl; Jakob R Passweg; Thomas Pabst; Johan Maertens; H Berna Beverloo; Marinus van Marwijk Kooy; Pierre W Wijermans; Bart J Biemond; Edo Vellenga; Leo F Verdonck; Gert J Ossenkoppele; Bob Löwenberg
Journal:  J Clin Oncol       Date:  2012-05-07       Impact factor: 44.544
  7 in total
  1 in total

1.  Oral hypomethylating agents: beyond convenience in MDS.

Authors:  Elizabeth A Griffiths
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.